Oral Oncology
Volume 40, Issue 8 , Pages 811-814, September 2004

Severe oral chronic graft-versus-host disease following allogeneic bone marrow transplantation: highly effective treatment with topical tacrolimus

  • André Eckardt

      Affiliations

    • Department of Oral and Maxillofacial Surgery, Hannover Medical School, Carl-Neuberg-Strasse 1, 30625 Hannover, Germany
    • Corresponding Author InformationCorresponding author. Tel.: +49-511-532-4878; fax: +49-511-532-8879
  • ,
  • Oliver Starke

      Affiliations

    • Department of Oral and Maxillofacial Surgery, Hannover Medical School, Carl-Neuberg-Strasse 1, 30625 Hannover, Germany
  • ,
  • Michael Stadler

      Affiliations

    • Department of Hematology, Hemostaseology and Oncology, Bone Marrow Transplantation Unit, Hannover Medical School, Carl-Neuberg-Strasse 1, 30625 Hannover, Germany
  • ,
  • Christoph Reuter

      Affiliations

    • Department of Hematology, Hemostaseology and Oncology, Bone Marrow Transplantation Unit, Hannover Medical School, Carl-Neuberg-Strasse 1, 30625 Hannover, Germany
  • ,
  • Bernd Hertenstein

      Affiliations

    • Department of Hematology, Hemostaseology and Oncology, Bone Marrow Transplantation Unit, Hannover Medical School, Carl-Neuberg-Strasse 1, 30625 Hannover, Germany

Received 2 February 2004; accepted 5 February 2004.

Abstract 

Oral involvement of chronic graft-versus-host disease (GvHD) is a most distressing and disabling complication of hematopoietic cell transplantation, for which systemic immunosuppression as well as topical corticosteroid treatment may offer only limited symptomatic relief. Here we report encouraging preliminary results with the application of tacrolimus (FK-506) as a 0.1% ointment in three patients with severe oral chronic GvHD, heavily pretreated without success, who experienced rapid, consistent, complete or at least marked, subjective and objective improvement with topical tacrolimus.

Keywords:  Bone marrow transplantation, Oral graft-versus-host disease, Tacrolimus

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S1368-8375(04)00048-X

doi:10.1016/j.oraloncology.2004.02.003

Oral Oncology
Volume 40, Issue 8 , Pages 811-814, September 2004